Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029

June 2023 | 900 pages | ID: G6009E5C286FEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029 Report Highlights:

• Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
• Global & Regional Antibody Drug Conjugate Market Insight
• Approved Drugs Sales Insight Global & Regional, Yearly & Quarterly, 2019 -2023
• Approved Antibody Drug Conjugates - Availability, Dosage & Price Insight
• Insight On Antibody Drug Conjugates In Clinical Trials: > 550 Drugs
• Insight On Commercially Approved Antibody Drug Conjugates: > 15 Drugs
• Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase
• Global Cancer Antibody Drug Conjugate Market Trends by Indication

The realm of cancer treatment is experiencing a surge of innovation that may greatly change how we currently diagnose as well as treat cancer. Clinical researchers and pharmaceutical companies continue to seek innovative solutions that offer enhanced efficacy and reduced side effects. Among the ongoing significant advancements, antibody drug conjugates (ADCs) have emerged as a groundbreaker in cancer therapeutics. This rapidly expanding market is transforming the treatment landscape, offering a new therapeutic option for patients globally.

Antibody drug conjugates harness the synergistic potential of monoclonal antibodies and potent cytotoxic drugs, delivering a strong strike against cancer cells. By exploiting the specificity of monoclonal antibodies, antibody drug conjugates can selectively bind to cancer antigens, increasing drug delivery directly to tumor sites. This targeted approach enables higher drug concentrations at the desired location while minimizing harm to healthy, normal tissues.

The antibody drug conjugate market is experiencing remarkable growth, driven by several key factors including the increasing cancer incidence rates, rowing demand for effective and personalized treatment options and advancements in antibody engineering and drug delivery technologies are propelling the market forward. Moreover, regulatory approvals have opened the way for the commercial success of antibody drug conjugates which has further encouraged investments in the field.

For instance, Adcetris and Kadcyla have been in the market for a long time and their commercial sales hold a significant share of the current antibody drug conjugate market. The growth of these antibody drug conjugates represents the significant need for this therapeutic modality. Enhertu, another antibody drug conjugate which is relatively new to the market compared to Kadcyla and Adcetris, has shown immense success commercially. With its recent approval for breast cancer indication, the sales for Enhertu have escalated rapidly.

Antibody drug conjugates have welcomed a new age of targeted cancer therapy and this novel class of cancer treatment can be evaluated to have an exponential increase in terms of both commercial success as well as expansion of the global portfolio. However, the development of antibody drug conjugates has been associated with significant challenges with difficulties in manufacturing, bioconjugation and their overall development. Nevertheless, collaboration between pharmaceutical companies and academic institutions has been an important factor that has helped in overcoming these limitations, resulting in such success of antibody drug conjugates.

For instance, Lantern Pharma collaborating with Germany’s Bielefeld University will leverage its proprietary Artificial Intelligence platform RADR for the rapid development of novel cryptophycin antibody drug conjugates, representing an exciting new class of strong and highly directed drug candidates. It is expected that outcomes from this collaborative arrangement will pave the way for next generation antibody drug conjugated designed using AI with high efficacy, swift development with sibilant cost reduction.

The future of antibody drug conjugates is expected to be closely tangled with technological innovations. Novel conjugation strategies such as site specific conjugation are also being explored to enhance stability of antibody drug conjugates, resulting in improved therapeutic outcomes. Additionally, advancements in bioconjugation techniques, payload release mechanism and drug delivery systems offer opportunities to optimize the pharmacokinetics and bio distribution of antibody drug conjugates potentially increasing their effectiveness.

Antibody drug conjugates have targeted a new level of efficacy, surpassing the capabilities of traditional monoclonal antibodies and opening opportunities for market expansion. While monoclonal antibodies are highly specific in their binding to cancer cell antigens, their therapeutic impact often relies on the activation of immune responses or blocking signaling pathways. In contrast, antibody drug conjugates offer a multifaceted approach by directly delivering a potent cytotoxic payload to cancer cells, exerting a direct cell killing effect.

Overall, the antibody drug conjugates market represents a groundbreaking approach to cancer treatment. As market continues to expand, patients and healthcare professionals are witnessing significant advancements. With ongoing research, technological innovations and strategic collaborations, the future of antibody drug conjugates is set to transform the global cancer therapy market. Our report provides a comprehensive analysis about the currently approved antibody drug conjugates in terms of their patent, price, dosage as well as their sales and treatment cost. Furthermore, the report also provides information about the regional impact of approved antibody drug conjugates while also providing information about the possible future opportunities in the global antibody drug conjugates market.

Contents

1. INTRODUCTION TO ANTIBODY DRUG CONJUGATES

1.1 Overview
1.2 Historical Development of ADCs
1.3 Evolution of Antibody Drug Conjugates

2. NEED OF ANTIBODY DRUG CONJUGATES

3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET INSIGHT

3.1 Current Market Scenario (2019 -2023)
3.2 Future Market Opportunity Assessment 2029

4. ANTIBODY DRUG CONJUGATE MARKET REGIONAL ANALYSIS

4.1 US
4.2 China
4.3 South Korea
4.4 India
4.5 Australia
4.6 Europe
4.7 Canada
4.8 Japan
4.9 Taiwan

5. GLOBAL CANCER ANTIBODY DRUG CONJUGATE MARKET TRENDS BY INDICATION

5.1 Breast Cancer
5.2 Lung Cancer
5.3 Lymphoma
5.4 Leukemia
5.5 Cervical Cancer
5.6 Urothelial Cancer
5.7 Gastric Cancer
5.8 Other Cancers

6. APPROVED ANTIBODY DRUG CONJUGATES - AVAILABILITY, DOSAGE & PRICE INSIGHT 2023

6.1 Mylotarg
6.2 Adcetris
6.3 Kadcyla
6.4 Besponsa
6.5 Lumoxiti
6.6 Polivy
6.7 Padcev
6.8 Enhertu
6.9 Trodelvy
6.10 Blenrep
6.11 Zynlonta
6.12 Tivdak
6.13 Elahere
6.14 Aidixi
6.15 Ujvira
6.16 Akalux

7. APPROVED ANTIBODY DRUG CONJUGATE SALES INSIGHTS (GLOBAL & REGIONAL, YEARLY & QUARTERLY, 2019 -2023)

7.1 Adcetris
7.2 Padcev
7.3 Tivdak
7.4 Polivy
7.5 Kadcyla
7.6 Besponsa
7.7 Enhertu
7.8 Trodelvy
7.9 Zynlonta
7.10 Elahere
7.11 Blenrep

8. GLOBAL ANTIBODY DRUG CONJUGATES CLINICAL TRIALS INSIGHT 2023

8.1 By Phase
8.2 By Indication
8.3 By Company
8.4 By Patient Segment
8.5 By Country

9. GLOBAL CANCER ANTIBODY DRUG CONJUGATES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
9.8 Preregistration

10. MARKETED CANCER ANTIBODY DRUG CONJUGATES CLINICAL INSIGHT

11. GLOBAL CANCER AN ANTIBODY DRUG CONJUGATES MARKET DYNAMICS

11.1 Favorable Parameters
11.2 Challenges for Antibody Drug conjugates Market

12. COMPETITIVE LANDSCAPE

12.1 AbbVie
12.2 ADC Therapeutics
12.3 AstraZeneca
12.4 Bayer
12.5 BiOneCure Therapeutics
12.6 Biosion
12.7 Bio-Thera Solutions
12.8 Boehringer Ingelheim
12.9 Daiichi Sankyo Company
12.10 Duality Biologics
12.11 Exelixis
12.12 Genmab
12.13 Hangzhou DAC Biotech
12.14 Heidelberg Pharma AG
12.15 Iksuda Therapeutics
12.16 ImmunoGen
12.17 LaNova Medicines Limited
12.18 LegoChem Biosciences
12.19 Lepu Biopharma
12.20 Mersana Therapeutics
12.21 Molecular Templates
12.22 Multitude Therapeutics
12.23 NanoValent Pharmaceuticals
12.24 NewBio Therapeutics
12.25 Orum Therapeutics
12.26 ProfoundBio
12.27 Radiopharm Theranostics
12.28 Seagen
12.29 Sorrento Therapeutics
12.30 Sutro Biopharma

List Of Figures

LIST OF FIGURES

Figure 1-1: Historical Development of Antibody Drug Conjugates
Figure 1-2: Approval History of Commercially Available Antibody Drug Conjugates
Figure 1-3: Classification of Antibody Drug Conjugates
Figure 2-1: Therapeutic Index – Antibody Drug Conjugate vs. Cytotoxic Drug
Figure 3-1: Global – Antibody Drug Conjugate Market (US$ Billion), 2019-2023*
Figure 3-2: Global – Sales of ADCs for Breast Cancer v/s other indications (%), 2022
Figure 3-3: Global – Antibody Drug Conjugate Market Forecast (US$ Billion), 2023 – 2029
Figure 4-1: Tubulis - P5 Conjugation Platform Antibody
Figure 4-2: US – Sales of Cancer Antibody Drug Conjugates (US$ Million), 2023
Figure 4-3: US – Sales of Cancer Antibody Drug Conjugates (%), 2023
Figure 4-4: US – Sales of Cancer Antibody Drug Conjugates (US$ Million), 2022
Figure 4-5: US – Sales of Cancer Antibody Drug Conjugates (%), 2022
Figure 4-6: Pinot Bio - PINOT-ADCTM Platform Working Mechanism
Figure 4-7: Alteogen - NexMab™ ADC technology
Figure 4-8: Canada – Cancer Incidence & Death, 2021
Figure 4-9: Adcetris - Canada Patents Numbers Approval & Expiration Dates
Figure 4-10: Padcev - Canada Patents Approval & Expiration Dates
Figure 4-11: Polivy - Canada Patents Numbers Approval & Expiration Dates
Figure 4-12: Enhertu - Canada Patents Numbers Approval & Expiration Dates
Figure 4-13: Trodelvy - Canada Patents Numbers Approval & Expiration Dates
Figure 4-14: Japan – Cancer Incidence & Death, 2022
Figure 6-1: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year
Figure 6-2: Mylotarg – Approval Year by Region
Figure 6-3: UK - Cost of Supply of Mylotarg 5 mg Intravenous Powder (GBP/US$), May’2023
Figure 6-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-5: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 6-6: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), May’2023
Figure 6-7: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 6-8: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 6-9: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 6-10: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), May’2023
Figure 6-11: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, May’2023
Figure 6-12: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 6-13: US - Adcetris FDA Approval Year by Indication
Figure 6-14: Adcetris - Approval Year by Region
Figure 6-15: Japan - Adcetris PMDA Approval Year by Indication
Figure 6-16: Adcetris - Patent Expiration by Region
Figure 6-17: Adcetris - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-18: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 6-19: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), May’2023
Figure 6-20: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 6-21: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), May’2023
Figure 6-22: Adcetris – Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), May’2023
Figure 6-23: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 6-24: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), May’2023
Figure 6-25: US - Kadcyla FDA Approval Year by Indication
Figure 6-26: Kadcyla - Approval Years by Region
Figure 6-27: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 6-28: US - Price for Single Unit of Kadcyla 100 mg & 160 mg Intravenous Powder for Injection (US$), May’2023
Figure 6-29: UK - Price for Single Unit of Kadcyla 100 mg & 160 mg Intravenous Powder for Injection (GBP/US$), May’2023
Figure 6-30: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-31: Kadcyla – Average Cost of Single Treatment Cycle for Early Stage HER2 Breast Cancer in Human with Average Weight (US$), May’2023
Figure 6-32: Kadcyla – Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
Figure 6-33: Besponsa - Approval Year by Region
Figure 6-34: UK - Cost of Supply of Besponsa 0.9 mg Intravenous Powder (GBP/US$), May’2023
Figure 6-35: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-36: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
Figure 6-37: Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
Figure 6-38: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), May’2023
Figure 6-39: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment (US$), May’2023
Figure 6-40: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)
Figure 6-41: Lumoxiti – Orphan Designation Years
Figure 6-42: Lumoxiti – Patent Expiry Years
Figure 6-43: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 6-44: Lumoxiti – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), May’2023
Figure 6-45: Polivy - Orphan Drug Designation Approval Year by Region
Figure 6-46: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 6-47: Polivy - Approval Year by Region
Figure 6-48: US - Price for Single Unit of Polivy 30 mg & 140 mg Intravenous Powder for Injection (US$), May’2023
Figure 6-49: UK - Price for Single Unit of Polivy 30 mg & 140 mg Intravenous Powder for Injection (GBP/US$), May’2023
Figure 6-50: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 6-51: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia with 30 mg Powder (US$), May’2023
Figure 6-52: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia with 140 mg Powder (US$), May’2023
Figure 6-53: Padcev - Approval Year by Region
Figure 6-54: US - Padcev FDA Approval & Patent Expiration Year
Figure 6-55: US - Price for Padcev 20 mg & 30 mg Intravenous Powder for Injection (US$), May’2023
Figure 6-56: UK - Price for Padcev 20 mg & 30 mg Intravenous Powder for Injection (GBP/US$), May’2023
Figure 6-57: Padcev – Average Cost of Single Dose & Single Treatment Cycle with 20 mg Powder (US$), May’2023
Figure 6-58: Padcev – Average Cost of Single Dose & Single Treatment Cycle with 30 mg Powder (US$), May’2023
Figure 6-59: Padcev – Recommended Minimum Dose & Dose after Reduction for Urothelial Cancer (mg/Kg)
Figure 6-60: Padcev – Recommended Maximum Dose & Dose after Reduction for Urothelial Cancer (mg)
Figure 6-61: Enhertu – FDA Orphan Drug Designation & Exclusivity Expiration Year
Figure 6-62: Enhertu - Approval Year by Region
Figure 6-63: US - Polivy FDA Approval Year by Indication
Figure 6-64: UK - Cost of Supply of Enhertu 100 mg Intravenous Powder (GBP/US$), May’2023
Figure 6-65: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-66: Enhertu – Recommended Dose by Cancer Type (mg/Kg)
Figure 6-67: Enhertu – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May’2023
Figure 6-68: Enhertu – Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)
Figure 6-69: Enhertu – Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)
Figure 6-70: US - Trodelvy FDA Approval by Indication
Figure 6-71: Trodelvy - Approval Year by Region
Figure 6-72: Trodelvy - Patent Expiration by Region
Figure 6-73: Trodelvy – Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US$), May’2023
Figure 6-74: Trodelvy – Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-75: Blenrep – FDA & EMA Orphan Drug Designations
Figure 6-76: Blenrep – FDA & EMA Approval
Figure 6-77: Blenrep - Cost of Supply of 100 mg Intravenous Powder in US, EU & UK (US$), May’2023
Figure 6-78: Blenrep – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May’2023
Figure 6-79: Blenrep – Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-80: Zynlonta - FDA & EMA Orphan Drug Designation Years
Figure 6-81: Zynlonta - FDA & EMA Approval Years
Figure 6-82: Zynlonta – Recommended Dose for Initial & Subsequent Cycles (mg/kg)
Figure 6-83: Zynlonta – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May’2023
Figure 6-84: Tivdak – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May’2023
Figure 6-85: Tivdak – Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-86: US - Price per Unit & Single Supply of Elahere 100 mg/20 mL Intravenous Solution (US$), May’2023
Figure 6-87: UK - Price for Single Unit of Elahere 100 mg/20 mL Intravenous Solution (GBP/US$), May’2023
Figure 6-88: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
Figure 6-89: India - Price for Single Unit of Ujvira 100 mg & 160 mg Intravenous Powder for Injection (INR/US$), May’2023
Figure 6-90: India - Price for Single Unit of Branded & Biosimilar Trastuzumab Emtansine 100 mg Powder for Injection (INR/US$), May’2023
Figure 6-91: Ujvira - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-92: Ujvira – Cost of Single Treatment Cycle with 100 mg & 160 mg Powder for Early Stage HER2+ Breast Cancer (INR/US$), May’2023
Figure 6-93: Ujvira – Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 6-94: Akalux - Sakigake Designation & PMDA Approval Year
Figure 7-1: Global - Adcetris Annual Sales (US$ Million), 2019-2023
Figure 7-2: Global - Adcetris Quarterly Sales (US$ Million), 2022
Figure 7-3: Global - Padcev Annual Sales (US$ Million), 2019-2023
Figure 7-4: Global - Padcev Quarterly Sales (US$ Million), 2022
Figure 7-5: Global - Tivdak Annual Sales (US$ Million), 2021-2023
Figure 7-6: Global - Tivdak Quarterly Sales (US$ Million), 2022
Figure 7-7: Global - Polivy Sales Values (US$ Million), 2019-2023
Figure 7-8: Regional - Polivy Sales (US$ Million), Q1’2023
Figure 7-9: Regional - Polivy Annual Sales (%), Q1’2023
Figure 7-10: Global - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-11: Regional - Polivy Annual Sales (US$ Million), 2022
Figure 7-12: Regional - Polivy Annual Sales (%), 2022
Figure 7-13: US – Polivy Annual Sales (US$ Million), 2019-2023
Figure 7-14: EU – Polivy Annual Sales (US$ Million), 2020-2023
Figure 7-15: ROW - Polivy Annual Sales (US$ Million), 2020-2023
Figure 7-16: US - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-17: Europe - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-18: ROW - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-19: Global - Kadcyla Annual Sales Value (US$ Million), 2019-2023
Figure 7-20: Regional - Kadcyla Sales (US$ Million), Q1’2023
Figure 7-21: Regional - Kadcyla Annual Sales (%), Q1’2023
Figure 7-22: Global - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-23: Regional - Kadcyla Annual Sales (US$ Million), 2022
Figure 7-24: Regional - Kadcyla Annual Sales (%), 2022
Figure 7-25: US – Kadcyla Annual Sales (US$ Million), 2019-2023
Figure 7-26: Europe – Kadcyla Annual Sales (US$ Million), 2020-2023
Figure 7-27: ROW - Kadcyla Annual Sales (US$ Million), 2020-2023
Figure 7-28: US - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-29: Europe - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-30: ROW - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-31: Global - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-32: Besponsa - Annual Sales by Region (US$ Million), Q1’2023
Figure 7-33: Besponsa - Quarterly Sales by Region (%), Q1’2023
Figure 7-34: Global - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-35: Regional - Besponsa Annual Sales (US$ Million), 2022
Figure 7-36: Regional - Besponsa Annual Sales (%), 2022
Figure 7-37: US - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-38: US - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-39: Europe - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-40: Europe - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-41: ROW - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-42: ROW - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-43: Global - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-44: Global - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-45: US - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-46: US - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-47: Europe - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-48: Europe - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-49: Japan - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-50: Japan - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-51: Global - Trodelvy Annual Sales (US$ Million), 2020-2023
Figure 7-52: Global - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-53: Regional - Trodelvy Annual Sales (%), 2022
Figure 7-54: Regional - Trodelvy Annual Sales (%), 2022
Figure 7-55: US - Trodelvy Annual Sales (US$ Million), 2020-2023
Figure 7-56: US - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-57: Europe - Trodelvy Annual Sales (US$ Million), 2021-2023
Figure 7-58: Europe - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-59: ROW - Trodelvy Annual Sales (US$ Million), 2022-2023
Figure 7-60: ROW - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-61: Global - Zynlonta Annual Sales (US$ Million), 2021-2023
Figure 7-62: Global - Zynlonta Quarterly Sales (US$ Million), 2022
Figure 7-63: Global - Elahere Annual Sales (US$ Million), 2022-2023
Figure 7-64: Global - Blenrep Annual Sales (Euro/US$ Million), 2020-2023
Figure 7-65: Regional - Blenrep Sales (Euro/US$ Million), Q1’2023
Figure 7-66: Regional – Blenrep Annual Sales (Euro/US$ Million), 2022
Figure 7-67: Regional – Blenrep Annual Sales (%), 2022
Figure 7-68: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2022
Figure 7-69: US - Blenrep Annual Sales (Euro/US$ Million), 2020-2023
Figure 7-70: US - Blenrep Quarterly Sales (Euro/US$ Million), 2022
Figure 7-71: Europe - Blenrep Annual Sales (Euro/US$ Million), 2020-2023
Figure 7-72: Europe - Blenrep Quarterly Sales (Euro/US$ Million), 2022
Figure 8-1: Global – Antibody Drug Conjugate In Clinical Trials By Phase, 2023
Figure 8-2: Global– Antibody Drug Conjugate In Clinical Trials By Indication, 2023
Figure 8-3: Global – Antibody Drug Conjugate In Clinical Trials By Company, 2023
Figure 8-4: Global – Antibody Drug Conjugate In Clinical Trials By Patient Segment, 2023
Figure 8-5: Global Antibody Drug Conjugate In Clinical Pipeline By Country, 2023
Figure 11-1: Antibody Drug conjugates Market Drivers
Figure 11-2: Challenges for Antibody Drug conjugates Market

List Of Tables

LIST OF TABLES

Table 3-1: Approved Cancer Antibody Drug Conjugates
Table 5-1: Breast Cancer – Candidates Under Clinical Development
Table 5-2: Lung Cancer – Some Candidates under Clinical development
Table 5-3: Lymphoma – Some Candidates under Clinical development
Table 5-4: Leukemia – Some Candidates under Clinical development
Table 5-5: Urothelial Cancer – Some Candidates under Clinical development
Table 5-6: Gastric Cancer – Some Candidates under Clinical development
Table 5-7: Recent FDA/EMA Designations to Investigational ADCs